← Leaderboards
Maureen A Chung
Rhode Island Hospital (Providence, Ri)
$314,399
Attributed
$314,399
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $136.2K · FY2005–09$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$314,399 · 4
By mechanism
P20$314,399 · 4
Top collaborators
No co-investigators on record.
Most similar at Rhode Island Hospital (Providence, Ri)
Same institution · by research overlap
- Douglas C Hixson$8,531,333
- Shuping Tong$4,499,602
- Stephen H. Gregory$4,415,926
- Gyorgy Baffy$974,288
- Edwin N Forman$139,715
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeNeoplasm /Cancer VaccineNeoplasm /CancerBcg VaccineCancer VaccinesCd AntigensCancer TherapyCenters Of Research ExcellenceClinical ResearchComputer Retrieval Of Information On Scientific Projects DatabaseDesignEmbryo /Fetus ProteinFetal ProteinsFundingGrantGene ExpressionHepatocellular CarcinomaHuman TissueInnovationInstitutionInterleukin-2Laboratory RatLiver CirrhosisCell Line
Grant awards (5)
COBRE: RIH: THEME A: FETAL PROTEINS & PHENOTYPES IN CANCER: NOVEL HCC VACCINES$28,440
P20 · FY2009 · RR · contact PI
COBRE: RIH: THEME A: FETAL PROTEINS & PHENOTYPES IN CANCER: NOVEL HCC VACCINES$24,331
P20 · FY2006 · RR · contact PI
COBRE: RIH: THEME A: FETAL PROTEINS &PHENOTYPES IN CANCER: NOVEL HCC VACCINES$136,185
P20 · FY2005 · RR
COBRE: RIH: THEME A: FETAL PROTEINS &PHENOTYPES IN CANCER: NOVEL HCC VACCINES$125,443
P20 · FY2004 · RR
Novel vaccines targetting CD155 and MUC1$0
P20 · FY2002 · RR